Method for reducing immunogenicity of therapeutic protein compositions
The present invention provides methods for reducing and/or evaluating the immunogenic potential of a therapeutic protein preparation. The present invention further provides pharmaceutical compositions of therapeutic proteins and methods of treatment with the same, the compositions having low immunogenic potential and/or improved efficacy. The invention achieves these goals by evaluating therapeutic protein preparations for subvisible protein particulates, which can contribute significantly to the overall immunogenic potential of the protein preparation. Further, by maintaining the content of such subvisible protein particulates to below an immunogenic threshold level, the resulting pharmaceutical composition is less likely to result in a loss of tolerance (e.g., upon repeated administration), thereby improving both the safety and efficacy profile of the therapeutic.
1. A method for reducing immunogenicity of a therapeutic protein, comprising:
providing a therapeutic protein preparation having at least 90% monomeric protein and greater than 2 ng/ml of subvisible particulates in the range of about 0.1 to about 10 microns in size;
determining high pressure conditions that reduce the subvisible particulates by at least 25% while favoring monomeric protein;
treating the therapeutic protein preparation with high pressure under said high pressure conditions, wherein a reduced level of said subvisible particulates is indicative of reduced immunogenicity.
2. The method of claim 1 , wherein the high pressure treatment is configured to reduce the amount of the subvisible particulates, as well as the amount of aggregates of greater than 10 microns in size, and/or the amount of aggregates of less than about 0.1 microns in size.
3. The method of claim 1 , wherein the subvisible particulates are reduced to below an immunogenic concentration.
4. The method of any claim 1 , wherein the subvisible particulates are quantified by micro-flow imaging, laser diffraction, or coulter counter.
5. The method of claim 4 , further comprising, formulating the therapeutic protein for subcutaneous, intramuscular, or intravenous administration.
6. The method of claim 1 , wherein the therapeutic protein comprises a monoclonal antibody, an antigen binding domain or single chain antibody, Fc-domain containing protein, an interleukin, interferon, protein hormone, peptide hormone, growth factor, clotting factor, or enzyme for replacement therapy.
7. The method of claim 1 , wherein the therapeutic protein preparation prior to high pressure treatment is greater than 90% monomeric material as determined by size exclusion chromatography (SEC).
8. The method of claim 7 , wherein the therapeutic protein preparation prior to high pressure treatment is substantially chromatographically pure as determined by SEC.
9. A pharmaceutical composition comprising a therapeutic protein prepared by the process of claim 1 .
10. The method of claim 1 , wherein the subvisible particulate content is quantified by micro-flow imaging.
11. The method of claim 1 , wherein the therapeutic protein preparation n and the conditions include high pressure in the range of about 1000 bar to about 2500 bar.
12. The method of claim 11 , wherein the etanercept preparation is substantially chromatographically pure as determined by SEC.
13. The method of claim 11 , wherein the subvisible particulates are quantified by micro-flow imaging, laser diffraction, or coulter counter.
14. The method of claim 11 , further comprising, formulating the therapeutic protein for subcutaneous, intramuscular, or intravenous administration.
15. The method of claim 1 , wherein the therapeutic protein preparation comprises at least 50 ng/ml of said subvisible particulates.
16. The method of claim 1 , wherein the therapeutic protein preparation comprises at least 100 ng/ml of said subvisible particulates.
17. The method of claim 1 , wherein the subvisible particulates are reduced at least 2-fold by the high pressure treatment.